|Bid||20.82 x 1200|
|Ask||20.86 x 2900|
|Day's range||20.50 - 21.00|
|52-week range||18.78 - 40.14|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||30.89|
LEXINGTON, Mass., October 19, 2021--Dicerna announced top-line results from its PHYOX4 study designed to evaluate the safety and tolerability of a single subcutaneous dose of nedosiran.
LEXINGTON, Mass., October 15, 2021--Dicerna announced an abstract on clinical data from the PHYOX™2 trial of nedosiran has been accepted as a late-breaker poster presentation at ASN.
LEXINGTON, Mass., October 14, 2021--Dicerna announced that two abstracts related to the Company’s clinical development programs have been accepted for poster presentations at AASLD.